Hck-IN-3 is an orally effective inhibitor targeting HCK (KD = 3.92 µM). Hck-IN-3 can inhibit the release of NO. Hck-IN-3 has an IC50 of 6.52 µM in RAW264.7 cells. Hck-IN-3 can inhibit the release of TNF-alpha, IL-6, and IL-1beta in a concentration dependent manner. Hck-IN-3 downregulates the protein expression of NLRP3, ASC, pro-caspase-1, and pro-IL-1beta in a concentration dependent manner. Hck-IN-3 can be used for research on acute non traumatic inflammatory conditions[1].
